Late Breaking Oral Abstract Podium Session

Abstract Presentations:

LB-1 SEMAGLUTIDE 2.4 MG EFFICACY AND SAFETY IN PEOPLE WITH OBESITY AND KNEE OSTEOARTHRITIS: RESULTS FROM THE STEP 9 RANDOMISED CLINICAL TRIAL
Henning Bliddal

LB-2 CRYOGENIC PHASE-ENHANCED X-RAY IMAGING OF UNFIXED, INTACT MOUSE KNEES REVEALS SHIFTING CHONDROCYTE PHENOTYPES AT THE OSTEOARTHRITIC ENDOCHONDRAL INTERFACE
Lucinda Evans

LB-3 SERUM INTESTINAL PERMEABILITY BIOMARKERS ARE ASSOCIATED WITH EROSIVE HAND OSTEOARTHRITIS AND RADIOGRAPHIC SEVERITY: RESULTS FROM THE DIGICOD COHORT
Marie Binvignat

LB-4 POST-TRAUMATIC OSTEOARTHRITIS MODEL IN AGED RATS ASSOCIATED WITH FUNCTIONAL BRAIN CHANGES
Jacob Griffith

LB-5 CR10049, THE FIRST OA-TARGETED KINASE INHIBITOR, IMPROVES PAIN BEHAVIOUR, RESOLVES INFLAMMATION AND PRESERVES JOINT STRUCTURE IN SMALL AND LARGE ANIMAL MODELS
Tiziana Piepoli